ERBB2 and breast carcinoma: Based on the promising clinical trial results of T-DXd in treating HER2-expressing breast and colorectal cancers, T-DXd therapy may be an effective treatment strategy for patients with small intestinal metastasis from breast cancer and our case report may contribute to the clinical experience of treating this condition with T-DXd (23, 27).